Chikungunya vaccine
| Vaccine description | |
|---|---|
| Target | Chikungunya virus |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | Ixchiq |
| AHFS/Drugs.com | Ixchiq |
| License data |
|
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status | |
A Chikungunya vaccine is a vaccine intended to provide acquired immunity against the chikungunya virus.
The most commonly reported side effects include headache, fatigue, muscle pain, joint pain, fever, nausea and tenderness at the injection site.. As of June 2025, use of the vaccine in elderly patients has been paused by medicines regulators in the US, EU and UK, while reports of serious neurological side effects and fatalities are investigated.
The first chikungunya vaccine was approved for medical use in the United States in November 2023. Chikungunya vaccines were also authorized in the European Union in May 2024.
As of May 9, 2025, the FDA and the CDC recommended healthcare providers should pause use of the chikungunya vaccine (Ixchiq) in patients over the age of 60 while the agencies investigate reports of serious neurologic, cardiac, and other adverse events in vaccine recipients.. The European Medicines Agency stopped the use of the vaccine in people over 65 on 7th May 2025 while on 18 June, the equivalent medicines regulator in the UK, the MHRA also stopped the use of the vaccine, which was due to be released in the UK market that day, in people over the age of 65.